Uncategorized
Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline
Sanofi; Vigil Neuroscience; acquisition; Alzheimer’s disease; TREM2 agonist; VG-3927; microglia; neurodegenerative disease; Phase 2 trials; biotech deals
HHS: All Branded Drugs Without Generic or Biosimilar Competition Must Abide by MFN Order Across All Markets
most-favored nation pricing; branded drugs; generic competition; biosimilar competition; HHS; executive order; drug pricing; pharmaceutical industry; OECD countries
FDA Expects ‘Timely Availability’ of Covid Shots as Advisors Update Formula Recommendation
FDA; Covid-19; vaccine; formula update; timely availability; advisory committee; JN.1-lineage; KP.2 strain; 2025-2026
Spotlight on LGBTQ+ Leaders Driving Change in Life Sciences
LGBTQ+ professionals; life sciences; biopharma; leadership; Diversity and Inclusion; Health Workforce; GUTC Fellows; philanthropy; Pride Month
Pharma Companies Eye ‘First Sale’ Rule to Lessen Tariff Costs Amid New US Trade Measures
first sale rule; pharmaceutical industry; US tariffs; customs loophole; drug import duties; tariff avoidance; trade compliance; Trump administration; de minimis exemption
Post-Hoc: AI bio needs to heed the overhyped history of CRISPR
CRISPR; AI in biotech; overhype; gene editing; reproductive health biotech
FDA Advisory Committee Unanimously Votes Against Expanding Pfizer’s Prostate Cancer Drug Combo
FDA; advisory committee; Pfizer; Talzenna; talazoparib; enzalutamide; prostate cancer; mCRPC; PARP inhibitor; label expansion; unanimous vote
Eikon Therapeutics Implements Second Major Staff Reduction in Under Two Years
Eikon Therapeutics; layoffs; biotech; staff cuts; funding cuts; research instrument development; workforce reduction; Roger Perlmutter
Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application
Moderna; mRNA-1083; combination vaccine; flu; COVID-19; FDA; Biologics License Application; vaccine efficacy; clinical trial; share price
FDA Advisory Committee Narrowly Votes Against UroGen’s Bladder Cancer Drug, Calls for Further Studies
FDA; UroGen Pharma; UGN-102; bladder cancer; Oncologic Drugs Advisory Committee; mitomycin; RCT; non–muscle invasive bladder cancer; clinical trials